<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535194</url>
  </required_header>
  <id_info>
    <org_study_id>16504</org_study_id>
    <secondary_id>I6T-MC-AMAJ</secondary_id>
    <secondary_id>2017-003286-10</secondary_id>
    <nct_id>NCT03535194</nct_id>
  </id_info>
  <brief_title>A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see how effective and safe mirikizumab is compared to
      secukinumab and placebo for moderate to severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 26, 2018</start_date>
  <completion_date type="Anticipated">April 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with a Static Physician's Global Assessment (sPGA) of (0,1) with at Least a 2-point Improvement from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of participants with an sPGA of (0,1) with at least a 2-point improvement from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants achieving a ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) from Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of participants achieving a ≥90% improvement in PASI 90 from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a 75% Improvement in PASI 75</measure>
    <time_frame>Week 4</time_frame>
    <description>Percentage of participants achieving a 75% improvement in PASI 75.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ≤1% of Body Surface Area (BSA) with Psoriasis Involvement</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of participants with ≤1% of BSA with psoriasis involvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 in Those with PSS Symptom Score of ≥1 at Baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of participants with a PSS symptoms score of 0 (free of itch, pain, stinging, and burning) in those with a PSS symptoms score of ≥1 at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1) with DLQI Baseline Score &gt;1</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of participants achieving DLQI (0,1) with DLQI baseline score &gt;1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants with Palmoplantar Involvement at Baseline</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Percent change from baseline in palmoplantar psoriasis severity index (PPASI) total score in participants with palmoplantar involvement at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants with Scalp Involvement at Baseline</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Percent change in PSSI total score in participants with scalp involvement at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants with Fingernail Involvement at Baseline</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Percent change from baseline in NAPSI total score in participants with fingernail involvement at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the 36-Item Short-Form Health Survey (SF-36) Physical Component Summary (PCS)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from baseline on the SF-36 PCS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the SF-36 Mental Component Summary (MCS)</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from baseline on the SF-36 MCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on Patient's Global Assessment (PatGA) of Disease Severity</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from baseline on PatGA of disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for the Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI-PSO) Scores</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from baseline for the WPAI PSO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Quick Inventory of Depressive Symptomatology(QIDS-SR16) Total Score in Those with a Baseline QIDS-SR16 Total Score ≥11.</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Change from baseline in QIDS-SR16 total score in those with a baseline QIDS-SR16 total score ≥11</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Mirikizumab</measure>
    <time_frame>Week 16</time_frame>
    <description>Minimum observed serum Ctrough,ss of mirikizumab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1443</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Mirikizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Secukinumab administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Mirikizumab</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Secukinumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have chronic plaque psoriasis for at least 6 months.

        Exclusion Criteria:

          -  Participant must not be breastfeeding or nursing woman.

          -  Participant must not have had serious, opportunistic, or chronic/recurring infection
             within 3 months.

          -  Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within
             12 months or received live vaccine(s) (including attenuated live vaccines) within 12
             weeks of baseline or intend to receive either during the study.

          -  Participant must not have any other skin conditions (excluding psoriasis).

          -  Participant must not have previous exposure to Cosentyx and any other biologic therapy
             targeting IL-17 (including Taltz).

          -  Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8
             weeks.

          -  Participant must not have previous exposure to any biologic therapy targeting IL-23
             (including Stelara).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>all 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interleukin-23 (IL-23)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

